Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.

Immune thrombocytopenia (ITP) is an autoimmune disorder characterised by both antibody-mediated platelet destruction and impaired megakaryocyte function. This results in decreased platelet counts and ...

This might sound surprising, but getting diagnosed with immune thrombocytopenia (also known as idiopathic thrombocytopenic purpura, or ITP) can come as a relief. You can figure out ITP treatment, of ...

An expert discusses how rilzabrutinib, a recently FDA-approved Bruton tyrosine kinase (BTK) inhibitor, targets the autoimmune ...

"The treatment paradigm of ITP is slowly shifting due to expanding experience with earlier use of TPO-RAs and TPO-mimetics in chronic and refractory ITP…Most of these agents are oral and better ...

New prospective research builds on a previous study that showed guidelines aren’t the main driver of treatment selection in pediatric patients with ITP. Of 12 potential reasons for prescribing ...

The addition of ianalumab to eltrombopag significantly prolonged the duration of safe platelet levels. Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in ...

The COVID-19 pandemic has reshaped daily life around the world. For many people living with chronic health conditions, the pandemic has been especially concerning. COVID-19 is a contagious respiratory ...

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first ...